Alterity Therapeutics Ltd (ATHE) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Alterity Therapeutics Ltd stock (ATHE) is currently trading at $3.33. Alterity Therapeutics Ltd PS ratio (Price-to-Sales) is 9.37. Analyst consensus price target for ATHE is $11.00. WallStSmart rates ATHE as Sell.
- ATHE PE ratio analysis and historical PE chart
- ATHE PS ratio (Price-to-Sales) history and trend
- ATHE intrinsic value — DCF, Graham Number, EPV models
- ATHE stock price prediction 2025 2026 2027 2028 2029 2030
- ATHE fair value vs current price
- ATHE insider transactions and insider buying
- Is ATHE undervalued or overvalued?
- Alterity Therapeutics Ltd financial analysis — revenue, earnings, cash flow
- ATHE Piotroski F-Score and Altman Z-Score
- ATHE analyst price target and Smart Rating
Alterity Therapeutics
📊 No data available
Try selecting a different time range
Smart Analysis
Alterity Therapeutics Ltd (ATHE) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Alterity Therapeutics Ltd (ATHE) Key Strengths (2)
Revenue surging 74.60% year-over-year
Trading at 1.56x book value, attractively priced
Supporting Valuation Data
Alterity Therapeutics Ltd (ATHE) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 9.4x annual revenue
Very low institutional interest at 1.80%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Alterity Therapeutics Ltd (ATHE) Detailed Analysis Report
Overall Assessment
This company scores 26/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 9.0/10) while 6 fall into concern territory (avg 1.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Price/Book. Valuation metrics including Price/Book (1.56) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 74.60%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (9.37) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -47.00%, Operating Margin at -372.60%, Profit Margin at -219.90%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -47.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 74.60% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ATHE Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ATHE's Price-to-Sales ratio of 9.37x sits near its historical average of 10.4x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 22% below its historical high of 11.99x set in Mar 2026, and 0% above its historical low of 9.37x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~11.8x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Alterity Therapeutics Ltd (ATHE) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Alterity Therapeutics Ltd is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 7M with 75% growth year-over-year. The company is currently unprofitable, posting a -219.9% profit margin.
Key Findings
Revenue growing at 75% YoY, reaching 7M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 116% of revenue (8M) on R&D, reinforcing its commitment to innovation and future growth.
The company is unprofitable with a -219.9% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -21M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Alterity Therapeutics Ltd maintain 75%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Alterity Therapeutics Ltd.
Bottom Line
Alterity Therapeutics Ltd is a high-conviction growth story with revenue accelerating at 75% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -219.9% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 11:32:45 AM
About Alterity Therapeutics Ltd(ATHE)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinson's disease and other neurodegenerative diseases in Australia. The company is headquartered in Melbourne, Australia.